Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Eiger BioPharmaceuticals ...

    NASDAQ: EIGR · Real-Time Price · USD
    1.73
    0.00 (0.29%)
    At close: Apr 03, 2024, 3:59 PM
    1.73
    0.00%
    After-hours: Jun 16, 2025, 04:00 PM EDT

    Eiger BioPharmaceuticals Statistics

    Share Statistics

    Eiger BioPharmaceuticals has 1.48M shares outstanding. The number of shares has increased by 0% in one year.

    Shares Outstanding

    n/a
    		 1.48M

    Shares Change (YoY)

    n/a
    		 0%

    Shares Change (QoQ)

    n/a
    		 0%

    Owned by Institutions (%)

    n/a
    		 n/a

    Shares Floating

    n/a
    		 1.27M

    Failed to Deliver (FTD) Shares

    n/a
    		 982

    FTD / Avg. Volume

    n/a
    		 0.74%

    Short Selling Information

    The latest short interest is 29.81K, so 0% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 29.81K

    Short % of Shares Out

    n/a
    		 n/a

    Short % of Float

    n/a
    		 n/a

    Short Ratio (days to cover)

    n/a
    		 1.06

    Valuation Ratios

    The PE ratio is -0.13 and the forward PE ratio is -0.64. Eiger BioPharmaceuticals's PEG ratio is 0.

    PE Ratio

    n/a
    		 -0.13

    Forward PE

    n/a
    		 -0.64

    PS Ratio

    n/a
    		 0.63

    Forward PS

    n/a
    		 0.1

    PB Ratio

    n/a
    		 -0.69

    P/FCF Ratio

    n/a
    		 -0.13

    PEG Ratio

    n/a
    		 0
    Financial Ratio History

    Enterprise Valuation

    Currently the Enterprise Value (EV) is not available for Eiger BioPharmaceuticals.

    EV / Sales

    n/a
    		 n/a

    EV / EBITDA

    n/a
    		 n/a

    EV / EBIT

    n/a
    		 n/a

    EV / FCF

    n/a
    		 n/a

    Financial Position

    The company has a current ratio of 0.71, with a Debt / Equity ratio of -2.85.

    Current Ratio

    n/a
    		 0.71

    Quick Ratio

    n/a
    		 0.68

    Debt / Equity

    n/a
    		 -2.85

    Debt / EBITDA

    n/a
    		 -0.6

    Debt / FCF

    n/a
    		 -0.55

    Interest Coverage

    n/a
    		 -13.13

    Financial Efficiency

    Return on Equity is n/a and Return on Invested Capital is n/a.

    Return on Equity

    n/a
    		 n/a

    Return on Assets

    n/a
    		 n/a

    Return on Invested Capital

    n/a
    		 n/a

    Revenue Per Employee

    n/a
    		 $281,660.71

    Profits Per Employee

    n/a
    		 $-1,338,625

    Employee Count

    n/a
    		 56

    Asset Turnover

    n/a
    		 0.41

    Inventory Turnover

    n/a
    		 0.02

    Taxes

    Income Tax

    n/a
    		 6K

    Effective Tax Rate

    n/a
    		 -0.01%

    Stock Price Statistics

    The stock price has increased by -28.81% in the last 52 weeks. The beta is 1.84, so Eiger BioPharmaceuticals's price volatility has been higher than the market average.

    Beta

    n/a
    		 1.84

    52-Week Price Change

    n/a
    		 -28.81%

    50-Day Moving Average

    n/a
    		 3.75

    200-Day Moving Average

    n/a
    		 9.4

    Relative Strength Index (RSI)

    n/a
    		 36.83

    Average Volume (20 Days)

    n/a
    		 131,879

    Income Statement

    In the last 12 months, Eiger BioPharmaceuticals had revenue of 15.77M and earned -74.96M in profits. Earnings per share was -50.78.

    Revenue

    n/a
    		 15.77M

    Gross Profit

    n/a
    		 15.75M

    Operating Income

    n/a
    		 -71.79M

    Net Income

    n/a
    		 -74.96M

    EBITDA

    n/a
    		 -68.74M

    EBIT

    n/a
    		 -69.49M

    Earnings Per Share (EPS)

    n/a
    		 -50.78
    Full Income Statement

    Balance Sheet

    The company has 25.44M in cash and 41.2M in debt, giving a net cash position of -15.76M.

    Cash & Cash Equivalents

    n/a
    		 25.44M

    Total Debt

    n/a
    		 41.2M

    Net Cash

    n/a
    		 -15.76M

    Retained Earnings

    n/a
    		 -512.16M

    Total Assets

    n/a
    		 38.83M

    Working Capital

    n/a
    		 -15.45M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -74.55M and capital expenditures -234K, giving a free cash flow of -74.78M.

    Operating Cash Flow

    n/a
    		 -74.55M

    Capital Expenditures

    n/a
    		 -234K

    Free Cash Flow

    n/a
    		 -74.78M

    FCF Per Share

    n/a
    		 -50.66
    Full Cash Flow Statement

    Margins

    Gross margin is 99.85%, with operating and profit margins of -455.12% and -475.26%.

    Gross Margin

    n/a
    		 99.85%

    Operating Margin

    n/a
    		 -455.12%

    Pretax Margin

    n/a
    		 -475.22%

    Profit Margin

    n/a
    		 -475.26%

    EBITDA Margin

    n/a
    		 -435.81%

    EBIT Margin

    n/a
    		 -455.12%

    FCF Margin

    n/a
    		 -474.11%

    Dividends & Yields

    EIGR does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 n/a

    FCF Yield

    n/a
    		 n/a
    Dividend Details

    Analyst Forecast

    Currently there are no analyst rating for EIGR.

    Price Target

    n/a
    		 n/a

    Price Target Difference

    n/a
    		 n/a

    Analyst Consensus

    n/a
    		 n/a

    Analyst Count

    n/a
    		 n/a
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Stock Splits

    The last stock split was on Jan 8, 2024. It was a backward split with a ratio of 1:30.

    Last Split Date

    n/a
    		 Jan 8, 2024

    Split Type

    n/a
    		 backward

    Split Ratio

    n/a
    		 1:30

    Scores

    Altman Z-Score

    n/a
    		 -24.48

    Piotroski F-Score

    n/a
    		 4

    Add to Watchlist